Core Insights - Gyre Therapeutics has appointed Dr. Dan Weng to its Board of Directors, effective August 18, 2025, which is seen as a pivotal moment for the company [1][4]. Company Overview - Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on fibrosis-first therapies for chronic diseases across various organ systems [1]. - The company’s flagship product, ETUARY (Pirfenidone capsule), was the first approved treatment for idiopathic pulmonary fibrosis (IPF) in the People's Republic of China (PRC) in 2011, achieving net sales of $105.0 million in 2024 [4]. - Gyre's pipeline includes Hydronidone, which has shown statistically significant fibrosis regression in a Phase 3 clinical trial for chronic hepatitis B (CHB)-associated liver fibrosis and is expected to file for New Drug Application (NDA) in Q3 2025 [4]. Leadership and Experience - Dr. Weng has nearly four decades of experience in managing global clinical trials and has held executive positions in various international contract research organizations (CROs) [2][4]. - His previous roles include President and CEO of Medelis, Inc., and Chairman and CEO of EPS International Holding Co., where he oversaw significant growth and corporate strategy [2]. Strategic Focus - Gyre Therapeutics aims to expand its commercial reach and advance its multinational pipeline, leveraging Dr. Weng's strategic insight and regulatory experience [4]. - The company is also developing treatments for various conditions, including Parkinson's disease (PD), diabetic kidney disease (DKD), radiation-induced lung injury (RILI), chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), and acute liver failure/acute-on-chronic liver failure (ALF/ACLF) [4][5].